Related references
Note: Only part of the references are listed.Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
George A. Diamond et al.
ANNALS OF INTERNAL MEDICINE (2007)
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis
Yusuf Yilmaz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Nonalcoholic fatty liver disease
LA Adams et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2005)
Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality
ER Miller et al.
ANNALS OF INTERNAL MEDICINE (2005)
Molecular mediators of hepatic steatosis and liver injury
JD Browning et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice
AM Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid
VN Santos et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2003)
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis
M Kiyici et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2003)
Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats
H Yoshiji et al.
HEPATOLOGY (2001)
Share Paper
